Send to

Choose Destination
Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc.

Intergroup Exemestane Study mature analysis: overall survival data.

Author information

Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland.


The findings of the Intergroup Exemestane Study (IES) challenge the standard adjuvant endocrine therapy consisting of 5 years of tamoxifen therapy in women with oestrogen receptor-positive breast cancer. The IES study confirmed that switching to an aromatase inhibitor (AI) such as exemestane after 2-3 years of tamoxifen therapy resulted in improved survival relative to women remaining on 5 years of tamoxifen therapy. Data from IES concur with the findings of other studies with AIs that support the rationale of switching from tamoxifen to an AI after 2-3 years of tamoxifen in postmenopausal women who remain disease-free.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center